The North America Vaccine Adjuvants Market would witness market growth of 3.5% CAGR during the forecast period (2023-2030).
Vaccinations are undoubtedly among the most remarkable advances in human health throughout history. In just over two centuries, vaccines have facilitated significant achievements, such as eradicating smallpox poliomyelitis and reducing morbidity and mortality related to multiple infectious illnesses. In many regions, vaccination policies are a cornerstone of public health, and great care is taken to ensure that the population receives safe and effective vaccines. Vaccine efficacy depends on its antigen elements and adjuvants, which are frequently employed to stimulate the immune system more effectively.
Adjuvants for human vaccines are substances introduced to vaccines to stimulate the recipient's immune system. These adjuvants enhance the efficacy of vaccines by enabling the immune system, which produces an immune response that is more robust and durable. Adjuvants are frequently necessary for combination vaccines to augment the immune system's reaction to numerous antigens that are administered concurrently. They encompass a range of substances that augment the effectiveness of vaccines through their administration in combination with vaccine antigens. Adjuvants may contain complex natural extracts, synthetic small molecule compounds, or particulate materials. Widespread use of adjuvants in vaccines has increased the efficacy of vaccination.
According to the Public Health Agency of Canada, cancer is expected to claim approximately 25% of Canadian citizens' lives. It will impact nearly half of the population in their lifetime. In this nation, the number of new cancer diagnoses and cancer-related fatalities continues to increase even though the aggregate risk of dying from cancer is decreasing. Population aging and expansion are the primary contributors to the progressive rise in cancer incidence and mortality; this trend is anticipated to persist in the decades to come. The rising number of cases of cancer in the region is consequently driving the growth of the market.
The US market dominated the North America Vaccine Adjuvants Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $599.6 Million by 2030. The Canada market is experiencing a CAGR of 5.8% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 4.9% during (2023 - 2030).
Based on Type, the market is segmented into Particulate, Adjuvant Emulsion, Pathogen, Combination, and Others. Based on Administration, the market is segmented into Intramuscular, Intranasal, Oral, Intradermal, and Others. Based on Application, the market is segmented into Infectious Diseases, Cancer, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Vaccine Adjuvants Market is Predict to reach $2.1 Billion by 2030, at a CAGR of 3.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC, Novavax, Inc., SPI Pharma, Inc. (Associated British Foods PLC), Agenus Inc., CSL Limited, InvivoGen SAS, Croda International PLC, Seppic S.A. (L’Air Liquide S.A.), Merck & Co., Inc. and Riboxx GmbH
Scope of the Study
Market Segments Covered in the Report:
By Type
- Particulate
- Adjuvant Emulsion
- Pathogen
- Combination
- Others
By Administration
- Intramuscular
- Intranasal
- Oral
- Intradermal
- Others
By Application
- Infectious Diseases
- Cancer
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC
- Novavax, Inc.
- SPI Pharma, Inc. (Associated British Foods PLC)
- Agenus Inc.
- CSL Limited
- InvivoGen SAS
- Croda International PLC
- Seppic S.A. (L’Air Liquide S.A.)
- Merck & Co., Inc.
- Riboxx GmbH
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Vaccine Adjuvants Market, by Type
1.4.2 North America Vaccine Adjuvants Market, by Administration
1.4.3 North America Vaccine Adjuvants Market, by Application
1.4.4 North America Vaccine Adjuvants Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb – 2023, Oct) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. North America Vaccine Adjuvants Market, by Type
5.1 North America Particulate Market, by Country
5.2 North America Adjuvant Emulsion Market, by Country
5.3 North America Pathogen Market, by Country
5.4 North America Combination Market, by Country
5.5 North America Others Market, by Country
Chapter 6. North America Vaccine Adjuvants Market, by Administration
6.1 North America Intramuscular Market, by Country
6.2 North America Intranasal Market, by Country
6.3 North America Oral Market, by Country
6.4 North America Intradermal Market, by Country
6.5 North America Others Market, by Country
Chapter 7. North America Vaccine Adjuvants Market, by Application
7.1 North America Infectious Diseases Market, by Country
7.2 North America Cancer Market, by Country
7.3 North America Others Market, by Country
Chapter 8. North America Vaccine Adjuvants Market, by Country
8.1 US Vaccine Adjuvants Market
8.1.1 US Vaccine Adjuvants Market, by Type
8.1.2 US Vaccine Adjuvants Market, by Administration
8.1.3 US Vaccine Adjuvants Market, by Application
8.2 Canada Vaccine Adjuvants Market
8.2.1 Canada Vaccine Adjuvants Market, by Type
8.2.2 Canada Vaccine Adjuvants Market, by Administration
8.2.3 Canada Vaccine Adjuvants Market, by Application
8.3 Mexico Vaccine Adjuvants Market
8.3.1 Mexico Vaccine Adjuvants Market, by Type
8.3.2 Mexico Vaccine Adjuvants Market, by Administration
8.3.3 Mexico Vaccine Adjuvants Market, by Application
8.4 Rest of North America Vaccine Adjuvants Market
8.4.1 Rest of North America Vaccine Adjuvants Market, by Type
8.4.2 Rest of North America Vaccine Adjuvants Market, by Administration
8.4.3 Rest of North America Vaccine Adjuvants Market, by Application
Chapter 9. Company Profiles
9.1 Novavax, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 SPI Pharma, Inc. (Associated British Foods PLC)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Agenus Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.6 SWOT Analysis
9.4 InvivoGen SAS
9.4.1 Company Overview
9.4.2 SWOT Analysis
9.5 Seppic S.A. (L’Air Liquide S.A.)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.5.6 SWOT Analysis
9.6 Riboxx GmbH
9.6.1 Company Overview
9.7 GlaxoSmithKline PLC (GSK)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials and Approvals:
9.7.6 SWOT Analysis
9.8 CSL Limited
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.6 SWOT Analysis
9.9 Croda International PLC
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Acquisition and Mergers:
9.10. Merck & Co., Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis
TABLE 1 North America Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 2 North America Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Vaccine Adjuvants Market
TABLE 4 Product Launches And Product Expansions– Vaccine Adjuvants Market
TABLE 5 Acquisition and Mergers– Vaccine Adjuvants Market
TABLE 6 Trials and Approvals- Vaccine Adjuvants Market
TABLE 7 North America Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 8 North America Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 9 North America Particulate Market, by Country, 2019 - 2022, USD Million
TABLE 10 North America Particulate Market, by Country, 2023 - 2030, USD Million
TABLE 11 North America Adjuvant Emulsion Market, by Country, 2019 - 2022, USD Million
TABLE 12 North America Adjuvant Emulsion Market, by Country, 2023 - 2030, USD Million
TABLE 13 North America Pathogen Market, by Country, 2019 - 2022, USD Million
TABLE 14 North America Pathogen Market, by Country, 2023 - 2030, USD Million
TABLE 15 North America Combination Market, by Country, 2019 - 2022, USD Million
TABLE 16 North America Combination Market, by Country, 2023 - 2030, USD Million
TABLE 17 North America Others Market, by Country, 2019 - 2022, USD Million
TABLE 18 North America Others Market, by Country, 2023 - 2030, USD Million
TABLE 19 North America Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 20 North America Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 21 North America Intramuscular Market, by Country, 2019 - 2022, USD Million
TABLE 22 North America Intramuscular Market, by Country, 2023 - 2030, USD Million
TABLE 23 North America Intranasal Market, by Country, 2019 - 2022, USD Million
TABLE 24 North America Intranasal Market, by Country, 2023 - 2030, USD Million
TABLE 25 North America Oral Market, by Country, 2019 - 2022, USD Million
TABLE 26 North America Oral Market, by Country, 2023 - 2030, USD Million
TABLE 27 North America Intradermal Market, by Country, 2019 - 2022, USD Million
TABLE 28 North America Intradermal Market, by Country, 2023 - 2030, USD Million
TABLE 29 North America Others Market, by Country, 2019 - 2022, USD Million
TABLE 30 North America Others Market, by Country, 2023 - 2030, USD Million
TABLE 31 North America Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 32 North America Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 33 North America Infectious Diseases Market, by Country, 2019 - 2022, USD Million
TABLE 34 North America Infectious Diseases Market, by Country, 2023 - 2030, USD Million
TABLE 35 North America Cancer Market, by Country, 2019 - 2022, USD Million
TABLE 36 North America Cancer Market, by Country, 2023 - 2030, USD Million
TABLE 37 North America Others Market, by Country, 2019 - 2022, USD Million
TABLE 38 North America Others Market, by Country, 2023 - 2030, USD Million
TABLE 39 North America Vaccine Adjuvants Market, by Country, 2019 - 2022, USD Million
TABLE 40 North America Vaccine Adjuvants Market, by Country, 2023 - 2030, USD Million
TABLE 41 US Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 42 US Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 43 US Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 44 US Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 45 US Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 46 US Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 47 US Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 48 US Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 49 Canada Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 50 Canada Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 51 Canada Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 52 Canada Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 53 Canada Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 54 Canada Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 55 Canada Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 56 Canada Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 57 Mexico Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 58 Mexico Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 59 Mexico Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 60 Mexico Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 61 Mexico Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 62 Mexico Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 63 Mexico Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 64 Mexico Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 65 Rest of North America Vaccine Adjuvants Market, 2019 - 2022, USD Million
TABLE 66 Rest of North America Vaccine Adjuvants Market, 2023 - 2030, USD Million
TABLE 67 Rest of North America Vaccine Adjuvants Market, by Type, 2019 - 2022, USD Million
TABLE 68 Rest of North America Vaccine Adjuvants Market, by Type, 2023 - 2030, USD Million
TABLE 69 Rest of North America Vaccine Adjuvants Market, by Administration, 2019 - 2022, USD Million
TABLE 70 Rest of North America Vaccine Adjuvants Market, by Administration, 2023 - 2030, USD Million
TABLE 71 Rest of North America Vaccine Adjuvants Market, by Application, 2019 - 2022, USD Million
TABLE 72 Rest of North America Vaccine Adjuvants Market, by Application, 2023 - 2030, USD Million
TABLE 73 Key Information – Novavax, Inc.
TABLE 74 Key Information – SPI Pharma, Inc.
TABLE 75 Key Information – Agenus Inc.
TABLE 76 Key Information – InvivoGen SAS
TABLE 77 Key Information – Seppic S.A.
TABLE 78 Key Information – Riboxx GmbH
TABLE 79 Key Information – GlaxoSmithKline PLC
TABLE 80 Key Information – CSL Limited
TABLE 81 Key Information – Croda International PLC
TABLE 82 Key Information - Merck & Co., Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Vaccine Adjuvants Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Vaccine Adjuvants Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Vaccine Adjuvants Market
FIG 8 North America Vaccine Adjuvants Market share, by Type, 2022
FIG 9 North America Vaccine Adjuvants Market share, by Type, 2030
FIG 10 North America Vaccine Adjuvants Market, by Type, 2019 - 2030, USD Million
FIG 11 North America Vaccine Adjuvants Market share, by Administration, 2022
FIG 12 North America Vaccine Adjuvants Market share, by Administration, 2030
FIG 13 North America Vaccine Adjuvants Market, by Administration, 2019 - 2030, USD Million
FIG 14 North America Vaccine Adjuvants Market share, by Application, 2022
FIG 15 North America Vaccine Adjuvants Market share, by Application, 2030
FIG 16 North America Vaccine Adjuvants Market, by Application, 2019 - 2030, USD Million
FIG 17 North America Vaccine Adjuvants Market share, by Country, 2022
FIG 18 North America Vaccine Adjuvants Market share, by Country, 2030
FIG 19 North America Vaccine Adjuvants Market, by Country, 2019 - 2030, USD Million
FIG 20 SWOT Analysis: Novavax, Inc.
FIG 21 SWOT Analysis: Agenus Inc.
FIG 22 SWOT Analysis: InvivoGen SAS
FIG 23 SWOT Analysis: Seppic S.A.
FIG 24 Recent strategies and developments: GlaxoSmithKline PLC
FIG 25 SWOT Analysis: GlaxoSmithKline PLC
FIG 26 SWOT Analysis: CSL Limited
FIG 27 SWOT Analysis: Merck & Co., Inc.